Inositec
inositec.com
Actively hiring
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
News
Vifor builds in kidney disease with Sanifit, Inositec buys
On the heels of a late-stage clinical trial failure, Vifor Pharma has moved to bolster its pipeline by acquiring Spain's Sanifit and fellow Swiss biotech Inositec for a combined value of €225 million (around $254 million) upfront. The deals mean Glattbrug
Read more
Report
Vifor Pharma to spearhead development of vascular calcification field, through acquisition of Sanifit Therapeutics and Inositec AG Financial Post
Read more
Report
Vifor builds in kidney disease with Sanifit, Inositec buys
On the heels of a late-stage clinical trial failure, Vifor Pharma has moved to bolster its pipeline by acquiring Spain's Sanifit and fellow Swiss biotech Inositec for a combined value of €225 million (around $254 million) upfront. The deals mean Glattbrug
Read more
Report
Report
Inositec Granted US Composition of Matter Patent for Cardiovascular Calcification Inhibitor INS-3001
Read more
Report
Inositec's INS-3001 Significantly Reduces Cardiovascular Calcification in Proof-of-Concept Studies Published in Nature Communications
Inositec, a pioneer in the development of life-saving small molecule drugs based on myo-inositol hexaphosphate (IP6), announced today that positive proof-of-concept data on INS-3001, a novel cardiovascular
Read more
Report